<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Neurodegener</journal-id><journal-title>Molecular Neurodegeneration</journal-title><issn pub-type="epub">1750-1326</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1750-1326-4-10</article-id><article-id pub-id-type="pmid">19200361</article-id><article-id pub-id-type="doi">10.1186/1750-1326-4-10</article-id><article-categories><subj-group subj-group-type="heading"><subject>Short Report</subject></subj-group></article-categories><title-group><article-title><italic>PGC-1alpha </italic>as modifier of onset age in Huntington disease</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Taherzadeh-Fard</surname><given-names>Elahe</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>elahe.taherzadeh@yahoo.com</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Saft</surname><given-names>Carsten</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>carsten.saft@rub.de</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Andrich</surname><given-names>J&#x000fc;rgen</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>juergen.andrich@rub.de</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Wieczorek</surname><given-names>Stefan</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Stefan.Wieczorek@ruhr-uni-bochum.de</email></contrib><contrib id="A5" corresp="yes" contrib-type="author"><name><surname>Arning</surname><given-names>Larissa</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>larissa.arning@rub.de</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Human Genetics, Ruhr-University, 44780 Bochum, Germany</aff><aff id="I2"><label>2</label>Department of Neurology, St. Josef-Hospital, Ruhr-University, 44791 Bochum, Germany</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>6</day><month>2</month><year>2009</year></pub-date><volume>4</volume><fpage>10</fpage><lpage>10</lpage><ext-link ext-link-type="uri" xlink:href="http://www.molecularneurodegeneration.com/content/4/1/10"/><history><date date-type="received"><day>19</day><month>12</month><year>2008</year></date><date date-type="accepted"><day>6</day><month>2</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 Taherzadeh-Fard et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Taherzadeh-Fard et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Taherzadeh-Fard Elahe elahe.taherzadeh@yahoo.com </dc:author><dc:title> PGC-1alpha as modifier of onset age in Huntington disease </dc:title><dc:date>2009</dc:date><dcterms:bibliographicCitation>Molecular Neurodegeneration 4(1): 10-. (2009)</dcterms:bibliographicCitation><dc:identifier type="sici">1750-1326(2009)4:1&#x0003c;10&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1750-1326</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><p>Although there is a strong correlation between CAG repeat length and age at onset (AO) of motor symptoms, individual Huntington disease (HD) patients may differ dramatically in onset age and disease manifestations despite similar CAG repeat lengths. This has led to a search for genetic factors that influence AO. In order to identify such a genetic modifier, we analysed polymorphisms in the <italic>PGC-1alpha </italic>gene. Recent data indicate inhibition of PGC-1alpha function by mutant Htt supporting a link between transcriptional deregulation and mitochondrial dysfunction in HD. In &#x0003e; 400 HD patients, a polymorphism located within intron 2, a potential recombination hot spot, explains a small, but statistically significant, amount of the variability in AO. Our data suggest that PGC-1alpha has modifying effects on the pathogenic process in HD.</p></abstract></article-meta></front><body><sec><title>Findings</title><p>Huntington Disease (HD) is an autosomal-dominant disorder due to lesions in the striatum that cause involuntary choreiform movements and progressive behavioral and cognitive impairment. The underlying mutation is an expansion of an unstable CAG repeat in the <italic>HD </italic>gene resulting in an expanded polyglutamine tract in huntingtin protein (Htt) [<xref ref-type="bibr" rid="B1">1</xref>]. HD shows highly variable clinical expression, as exemplified by the wide variation of AO. The strong inverse relationship between AO and number of CAG repeats is well-defined. Yet, there is substantial variation in AO that is not explained by the HD repeat [<xref ref-type="bibr" rid="B2">2</xref>-<xref ref-type="bibr" rid="B6">6</xref>].</p><p>To date, several genetic modifiers of HD have been described in independent studies. All of these modifiers relate to various mechanisms implicated in HD pathology such as excitotoxicity, dopamine toxicity, metabolic impairment, transcription deregulation, protein misfolding and oxidative stress [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B11">11</xref>]. Additionally, genomewide linkage scans revealed potential loci that may contain genes that modify AO [<xref ref-type="bibr" rid="B12">12</xref>-<xref ref-type="bibr" rid="B14">14</xref>].</p><p>Increasing evidence implicates mitochondrial dysfunction and metabolic impairment in HD pathology [for review see [<xref ref-type="bibr" rid="B15">15</xref>]]. In particular, PGC-1alpha (peroxisome proliferator-activated receptor [PPAR]-g coactivator 1a) as a key transcriptional co-regulator is an important mediator in protecting neurons against oxidative damage and seems to be involved in HD pathogenesis. PGC-1alpha induces the transcription of cellular programs regulating mitochondrial respiration, oxidative stress defense and adaptive thermogenesis [<xref ref-type="bibr" rid="B16">16</xref>]. Recent data indicate inhibition of PGC-1alpha function by mutant Htt supporting a link between transcriptional deregulation and mitochondrial dysfunction in HD [<xref ref-type="bibr" rid="B17">17</xref>-<xref ref-type="bibr" rid="B19">19</xref>]. Altered PGC-1alpha function may, therefore, contribute to HD pathogenesis.</p><p>A total of 15 single nucleotide polymorphisms (SNPs) in the peroxisome proliferators-activated receptor &#x003b3; coactivator 1 &#x003b1; (PPARGC1A) gene (rs2970865, rs2970866, rs4383605, rs2946386, rs2970869, rs17576121, rs2970870, rs7695542, rs2970873, rs2946385, rs12374310, rs7665116, rs2970855, rs2970848, rs8192678) were selected for genotyping in a German HD cohort of more than 400 unrelated patients recruited from the Huntington Center NRW in Bochum. Clinical assessment and determination of the motor AO was performed exclusively by experienced neurologists of the Center. The expanded CAG repeats ranged from 40 to 66 trinucleotide units and AO ranged from 16 to 76 years of age, with a mean of 45 years. <italic>HD </italic>CAG repeat sizes were determined by polymerase chain reaction using an assay counting the perfectely repeated (CAG)<sub>n </sub>units. Informed consent was obtained from all patients and controls. The studies were performed in a manner that fully complies with the Code of Ethics of the World Medical Association (Declaration of Helsinki) and was approved by the relevant university review board.</p><p>The polymorphisms were selected from NCBI SNP database due to their potential functional relevance, <italic>e.g. </italic>polymorphisms in the 5'-UTR were included due to their potential to influence gene expression, and their relative frequency. The genotype distributions of all the chosen polymorphisms were consistent with Hardy-Weinberg equilibrium (HWE).</p><p>Controlling for the effect of CAG repeat length on AO revealed an R<sup>2 </sup>value of 0.729 indicating that nearly 73% of the variation in AO could be explained by the mutation itself (Table <xref ref-type="table" rid="T1">1</xref>). In addition to the number of the expanded CAG repeats, the modifying effects of the polymorphisms in <italic>PGC-1alpha </italic>on the AO were examined.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Variability in AO attributable to the CAG repeat length was assessed by linear regression using the logarithmically transformed AO as the dependent variable and SNP genotypes as independent variables.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left" colspan="2"><bold>Model</bold></td><td align="center"><bold>R<sup>2</sup></bold></td><td align="center"><bold>&#x00394;R<sup>2</sup></bold></td><td align="center"><bold>% additionally explained variance</bold></td><td align="center"><bold><italic>P </italic>value</bold></td></tr></thead><tbody><tr><td align="left" colspan="2">HD CAG 40&#x02013;66 (n = 401)</td><td align="center">0.729</td><td align="center">-</td><td></td><td align="center">&#x0003c; 0.0005</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left" colspan="2"><bold><italic>PGC-1alpha </italic>Polymorphis ms</bold></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">rs2970865</td><td align="center">promoter region</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">-</td></tr><tr><td align="left">rs2970866</td><td align="center">promoter region</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">-</td></tr><tr><td align="left">rs4383605</td><td align="center">promoter region</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">-</td></tr><tr><td align="left">rs2946386</td><td align="center">promoter region</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">-</td></tr><tr><td align="left">rs2970869</td><td align="center">promoter region</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">-</td></tr><tr><td align="left">rs17576121</td><td align="center">promoter region</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">-</td></tr><tr><td align="left">rs2970870</td><td align="center">promoter region</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">-</td></tr><tr><td align="left">rs7695542</td><td align="center">promoter region</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">-</td></tr><tr><td align="left">rs2970873</td><td align="center">intron1</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">-</td></tr><tr><td align="left">rs2946385</td><td align="center">intron2</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">-</td></tr><tr><td align="left">rs12374310</td><td align="center">intron2</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">-</td></tr><tr><td align="left"><bold>rs7665116</bold></td><td align="center"><bold>intron2</bold></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><bold>0,1,2</bold></td><td></td><td align="center"><bold>0.732</bold></td><td align="center"><bold>0.003</bold></td><td align="center"><bold>1.1</bold></td><td align="center"><bold>0.025</bold></td></tr><tr><td align="left"><bold>0,1,1</bold></td><td></td><td align="center"><bold>0.733</bold></td><td align="center"><bold>0.004</bold></td><td align="center"><bold>1.5</bold></td><td align="center"><bold>0.012</bold></td></tr><tr><td align="left">rs2970855</td><td align="center">intron5</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">-</td></tr><tr><td align="left">rs2970848</td><td align="center">intron7</td><td align="center">0.731</td><td align="center">-</td><td align="center">-</td><td align="center">0.054</td></tr><tr><td align="left">rs8192678</td><td align="center">exon 8</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">-</td></tr></tbody></table><table-wrap-foot><p>R<sup>2 </sup>illustrates the relative improvement of the regression model when the genotypes are considered in addition to the CAG repeats; &#x00394;R<sup>2 </sup>values quantify these differences. (-) indicates no increase in R<sup>2</sup>.</p></table-wrap-foot></table-wrap><p>Here, we saw evidence of association of the rs7665116 SNP. The R<sup>2 </sup>statistic rose modestly but significantly (from 0.729 to 0.732, p = 0.025 in the additive model, TT vs TC vs CC, and from 0.729 to 0.733, p = 0.012, in the dominant model, TT vs TC+CC) when rs7665116 genotypes were added to the regression model (Table <xref ref-type="table" rid="T1">1</xref>). The mean AO in patients homozygous for the wildtype allele T is 45.08 years of age, while the mean AO for patients homozygous for the C allele is 47.3 years of age. SNP rs2970848 in intron 7 shows a trend towards association, for all other polymoprhism no impact on the R<sup>2 </sup>statistic could be observed.</p><p>Figure <xref ref-type="fig" rid="F1">1</xref> shows the HapMap r<sup>2 </sup>values among these SNPs in the HD cohort and reflects the previously reported rough subdivision into 2 main haplotype blocks [<xref ref-type="bibr" rid="B20">20</xref>]. The first one includes the polymorphisms in the promoter region and intron 1 (rs2970865, rs2970866, rs4383605, rs2946386, rs2970869, rs17576121, rs2970870, rs7695542, rs2970873), whereas the second includes the SNPs located 3' downstream of rs7665116 in intron 2. The two haplotype blocks are separated by a region of high recombination frequency. These results comply with the HapMap database.</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Schematic representation of the <italic>PGC-1alpha </italic>gene and linkage disequilibrium (r2) in the analysed HD cohort</bold>. Black boxes and a horizontal line represent exons and introns respectively. The numbers in the cells denote the r<sup>2 </sup>between the two SNPs corresponding to the cell. Cell shading indicates strength of r<sup>2 </sup>as shown by the number.</p></caption><graphic xlink:href="1750-1326-4-10-1"/></fig><p>The rs7665116 T &#x0003e; C polymorphism is located within intron 2, a potential recombination hot spot. Sequence alignments of multiple species show that this SNP is located at the beginning of a 233 bp highly conserved sequence. Yet, the rs7665116 polymorphism itself is not conserved to any significant extent across species. No other SNPs are described in this conserved sequence.</p><p><italic>In silico</italic>-analysis of rs7665116 using MatInspector [<xref ref-type="bibr" rid="B21">21</xref>] revealed loss of potential binding sites for cAMP-responsive element binding proteins (V$CHOP.01) in case of the C allele as compared to the wildtype T allele. On the other hand, in case of the C allele a new binding site is generated for v-Myb (V$VMYB.02) and X-box binding protein RFX1 (V$RFX1.01). Yet, it can only be speculated that the conserved region around rs7665116 represents a regulatory region controlling constitutive functions of <italic>PGC-1alpha</italic>. Functional studies are needed to assess whether <italic>PGC-1alpha </italic>is a true modifier gene and to identify the causal genetic variations contributing in the pathogenesis of HD in this region.</p><p>While this manuscript was under review, an article by Weydt <italic>et al. </italic>was published in this journal showing a modifying effect of <italic>PGC-1alpha </italic>haploblock 2 variations upon AO in an Italian cohort of 447 unrelated HD patients [<xref ref-type="bibr" rid="B22">22</xref>]. Our independent confirmation of their findings in a German cohort strengthens the conclusion that the <italic>PGC-1alpha </italic>gene appears to have modifying effects on the pathogenic process in HD and that it may be a therapeutically useful target for development of a treatment. Yet, it will be necessary to delineate of the precise basis for the <italic>PGC-1alpha </italic>modifier effect in order to effectively undertake a search for chemical compounds that delay HD onset.</p></sec><sec><title>Abbreviations</title><p>PGC-1<italic>alpha</italic>: peroxisome proliferator-activated receptor gamma co-activator</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>ETF carried out the molecular genetic studies and helped to design the study and draft the manuscript. CS and JA had ascertained the clinical status of the patients. SW interpreted the data and reviewed the manuscript. LA designed the study including statistical analysis and drafted the manuscript.</p></sec></body><back><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><collab>The Huntington's Disease Collaborative Research Group</collab></person-group><article-title>A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes</article-title><source>Cell</source><year>1993</year><volume>72</volume><fpage>971</fpage><lpage>983</lpage><pub-id pub-id-type="pmid">8458085</pub-id><pub-id pub-id-type="doi">10.1016/0092-8674(93)90585-E</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Snell</surname><given-names>RG</given-names></name><name><surname>MacMillan</surname><given-names>JC</given-names></name><name><surname>Cheadle</surname><given-names>JP</given-names></name><name><surname>Fenton</surname><given-names>I</given-names></name><name><surname>Lazarou</surname><given-names>LP</given-names></name><name><surname>Davies</surname><given-names>P</given-names></name><name><surname>MacDonald</surname><given-names>ME</given-names></name><name><surname>Gusella</surname><given-names>JF</given-names></name><name><surname>Harper</surname><given-names>PS</given-names></name><name><surname>Shaw</surname><given-names>DJ</given-names></name></person-group><article-title>Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease</article-title><source>Nat Genet</source><year>1993</year><volume>4</volume><fpage>393</fpage><lpage>397</lpage><pub-id pub-id-type="pmid">8401588</pub-id><pub-id pub-id-type="doi">10.1038/ng0893-393</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Andrew</surname><given-names>SE</given-names></name><name><surname>Goldberg</surname><given-names>YP</given-names></name><name><surname>Kremer</surname><given-names>B</given-names></name><name><surname>Telenius</surname><given-names>H</given-names></name><name><surname>Theilmann</surname><given-names>J</given-names></name><name><surname>Adam</surname><given-names>S</given-names></name><name><surname>Starr</surname><given-names>E</given-names></name><name><surname>Squitieri</surname><given-names>F</given-names></name><name><surname>Lin</surname><given-names>B</given-names></name><name><surname>Kalchman</surname><given-names>MA</given-names></name><etal></etal></person-group><article-title>The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease</article-title><source>Nat Genet</source><year>1993</year><volume>4</volume><fpage>398</fpage><lpage>403</lpage><pub-id pub-id-type="pmid">8401589</pub-id><pub-id pub-id-type="doi">10.1038/ng0893-398</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Duyao</surname><given-names>M</given-names></name><name><surname>Ambrose</surname><given-names>C</given-names></name><name><surname>Myers</surname><given-names>R</given-names></name><name><surname>Novelletto</surname><given-names>A</given-names></name><name><surname>Persichetti</surname><given-names>F</given-names></name><name><surname>Frontali</surname><given-names>M</given-names></name><name><surname>Folstein</surname><given-names>S</given-names></name><name><surname>Ross</surname><given-names>C</given-names></name><name><surname>Franz</surname><given-names>M</given-names></name><name><surname>Abbott</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Trinucleotide repeat length instability and age of onset in Huntington's disease</article-title><source>Nat Genet</source><year>1993</year><volume>4</volume><fpage>387</fpage><lpage>392</lpage><pub-id pub-id-type="pmid">8401587</pub-id><pub-id pub-id-type="doi">10.1038/ng0893-387</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kehoe</surname><given-names>P</given-names></name><name><surname>Krawczak</surname><given-names>M</given-names></name><name><surname>Harper</surname><given-names>PS</given-names></name><name><surname>Owen</surname><given-names>MJ</given-names></name><name><surname>Jones</surname><given-names>AL</given-names></name></person-group><article-title>Age of onset in Huntington disease: sex specific influence of apolipoprotein E genotype and normal CAG repeat length</article-title><source>J Med Genet</source><year>1999</year><volume>36</volume><fpage>108</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">10051007</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><collab>The U.S.-Venezuela Collaborative Research Project and Wexler NS</collab></person-group><article-title>Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset</article-title><source>Proc Natl Acad Sci USA</source><year>2004</year><volume>101</volume><fpage>3498</fpage><lpage>3503</lpage><pub-id pub-id-type="pmid">14993615</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0308679101</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Metzger</surname><given-names>S</given-names></name><name><surname>Bauer</surname><given-names>P</given-names></name><name><surname>Tomiuk</surname><given-names>J</given-names></name><name><surname>Laccone</surname><given-names>F</given-names></name><name><surname>Didonato</surname><given-names>S</given-names></name><name><surname>Gellera</surname><given-names>C</given-names></name><name><surname>Soliveri</surname><given-names>P</given-names></name><name><surname>Lange</surname><given-names>HW</given-names></name><name><surname>Weirich-Schwaiger</surname><given-names>H</given-names></name><name><surname>Wenning</surname><given-names>GK</given-names></name><etal></etal></person-group><article-title>The S18Y polymorphism in the UCHL1 gene is a genetic modifier in Huntington's disease</article-title><source>Neurogenetics</source><year>2006</year><volume>7</volume><fpage>27</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">16369839</pub-id><pub-id pub-id-type="doi">10.1007/s10048-005-0023-z</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arning</surname><given-names>L</given-names></name><name><surname>Saft</surname><given-names>C</given-names></name><name><surname>Wieczorek</surname><given-names>S</given-names></name><name><surname>Andrich</surname><given-names>J</given-names></name><name><surname>Kraus</surname><given-names>PH</given-names></name><name><surname>Epplen</surname><given-names>JT</given-names></name></person-group><article-title>NR2A and NR2B receptor gene variations modify age at onset in Huntington disease in a sex-specific manner</article-title><source>Hum Genet</source><year>2007</year><volume>122</volume><fpage>175</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">17569088</pub-id><pub-id pub-id-type="doi">10.1007/s00439-007-0393-4</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Andresen</surname><given-names>JM</given-names></name><name><surname>Gayan</surname><given-names>J</given-names></name><name><surname>Cherny</surname><given-names>SS</given-names></name><name><surname>Brocklebank</surname><given-names>D</given-names></name><name><surname>Alkorta-Aranburu</surname><given-names>G</given-names></name><name><surname>Addis</surname><given-names>EA</given-names></name><name><surname>Cardon</surname><given-names>LR</given-names></name><name><surname>Housman</surname><given-names>DE</given-names></name><name><surname>Wexler</surname><given-names>NS</given-names></name></person-group><article-title>Replication of twelve association studies for Huntington's disease residual age of onset in large Venezuelan kindreds</article-title><source>J Med Genet</source><year>2007</year><volume>44</volume><fpage>44</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">17018562</pub-id><pub-id pub-id-type="doi">10.1136/jmg.2006.045153</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arning</surname><given-names>L</given-names></name><name><surname>Mont&#x000e9;</surname><given-names>D</given-names></name><name><surname>Hansen</surname><given-names>W</given-names></name><name><surname>Wieczorek</surname><given-names>S</given-names></name><name><surname>Jagiello</surname><given-names>P</given-names></name><name><surname>Akkad</surname><given-names>DA</given-names></name><name><surname>Andrich</surname><given-names>J</given-names></name><name><surname>Kraus</surname><given-names>PH</given-names></name><name><surname>Saft</surname><given-names>C</given-names></name><name><surname>Epplen</surname><given-names>JT</given-names></name></person-group><article-title>ASK1 and MAP2K6 as modifiers of age at onset in Huntington's disease</article-title><source>J Mol Med</source><year>2008</year><volume>86</volume><fpage>485</fpage><lpage>490</lpage><pub-id pub-id-type="pmid">18327563</pub-id><pub-id pub-id-type="doi">10.1007/s00109-007-0299-6</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Metzger</surname><given-names>S</given-names></name><name><surname>Rong</surname><given-names>J</given-names></name><name><surname>Nguyen</surname><given-names>HP</given-names></name><name><surname>Cape</surname><given-names>A</given-names></name><name><surname>Tomiuk</surname><given-names>J</given-names></name><name><surname>Soehn</surname><given-names>AS</given-names></name><name><surname>Propping</surname><given-names>P</given-names></name><name><surname>Freudenberg-Hua</surname><given-names>Y</given-names></name><name><surname>Freudenberg</surname><given-names>J</given-names></name><name><surname>Tong</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>SH</given-names></name><name><surname>Li</surname><given-names>XJ</given-names></name><name><surname>Riess</surname><given-names>O</given-names></name></person-group><article-title>Huntingtin-associated protein-1 is a modifier of the age-at-onset of Huntington's disease</article-title><source>Hum Mol Genet</source><year>2008</year><volume>17</volume><fpage>1137</fpage><lpage>1146</lpage><pub-id pub-id-type="pmid">18192679</pub-id><pub-id pub-id-type="doi">10.1093/hmg/ddn003</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>JL</given-names></name><name><surname>Hayden</surname><given-names>MR</given-names></name><name><surname>Almqvist</surname><given-names>EW</given-names></name><name><surname>Brinkman</surname><given-names>RR</given-names></name><name><surname>Durr</surname><given-names>A</given-names></name><name><surname>Dode</surname><given-names>C</given-names></name><name><surname>Morrison</surname><given-names>PJ</given-names></name><name><surname>Suchowersky</surname><given-names>O</given-names></name><name><surname>Ross</surname><given-names>CA</given-names></name><name><surname>Margolis</surname><given-names>RL</given-names></name><etal></etal></person-group><article-title>A genome scan for modifiers of age at onset in Huntington disease: The HD MAPS study</article-title><source>Am J Hum Genet</source><year>2003</year><volume>73</volume><fpage>682</fpage><lpage>687</lpage><pub-id pub-id-type="pmid">12900792</pub-id><pub-id pub-id-type="doi">10.1086/378133</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>JL</given-names></name><name><surname>Hayden</surname><given-names>MR</given-names></name><name><surname>Warby</surname><given-names>SC</given-names></name><name><surname>Durr</surname><given-names>A</given-names></name><name><surname>Morrison</surname><given-names>PJ</given-names></name><name><surname>Nance</surname><given-names>M</given-names></name><name><surname>Ross</surname><given-names>CA</given-names></name><name><surname>Margolis</surname><given-names>RL</given-names></name><name><surname>Rosenblatt</surname><given-names>A</given-names></name><name><surname>Squitieri</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>Genome-wide significance for a modifier of age at neurological onset in Huntington's disease at 6q23-24: the HD MAPS study</article-title><source>BMC Med Genet</source><year>2006</year><volume>7</volume><fpage>71</fpage><pub-id pub-id-type="pmid">16914060</pub-id><pub-id pub-id-type="doi">10.1186/1471-2350-7-71</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gay&#x000e1;n</surname><given-names>J</given-names></name><name><surname>Brocklebank</surname><given-names>D</given-names></name><name><surname>Andresen</surname><given-names>JM</given-names></name><name><surname>Alkorta-Aranburu</surname><given-names>G</given-names></name><collab>US-Venezuela Collaborative Research Group</collab><name><surname>Zameel Cader</surname><given-names>M</given-names></name><name><surname>Roberts</surname><given-names>SA</given-names></name><name><surname>Cherny</surname><given-names>SS</given-names></name><name><surname>Wexler</surname><given-names>NS</given-names></name><name><surname>Cardon</surname><given-names>LR</given-names></name><name><surname>Housman</surname><given-names>DE</given-names></name></person-group><article-title>Genomewide linkage scan reveals novel loci modifying age of onset of Huntington's disease in the Venezuelan HD kindreds</article-title><source>Genet Epidemiol</source><year>2008</year><volume>5</volume><fpage>445</fpage><lpage>453</lpage><pub-id pub-id-type="doi">10.1002/gepi.20317</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gil</surname><given-names>JM</given-names></name><name><surname>Rego</surname><given-names>AC</given-names></name></person-group><article-title>Mechanisms of neurodegeneration in Huntington's disease</article-title><source>Eur J Neurosci</source><year>2008</year><volume>27</volume><fpage>2803</fpage><lpage>2820</lpage><pub-id pub-id-type="pmid">18588526</pub-id><pub-id pub-id-type="doi">10.1111/j.1460-9568.2008.06310.x</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Puigserver</surname><given-names>P</given-names></name><name><surname>Spiegelman</surname><given-names>BM</given-names></name></person-group><article-title>Peroxisome proliferatoractivated receptor-g coactivator 1a (PGC-1a): transcriptional coactivator and metabolic regulator</article-title><source>Endocr Rev</source><year>2003</year><volume>24</volume><fpage>78</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">12588810</pub-id><pub-id pub-id-type="doi">10.1210/er.2002-0012</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>L</given-names></name><name><surname>Jeong</surname><given-names>H</given-names></name><name><surname>Borovecki</surname><given-names>F</given-names></name><name><surname>Parkhurst</surname><given-names>CN</given-names></name><name><surname>Tanese</surname><given-names>N</given-names></name><name><surname>Krainc</surname><given-names>D</given-names></name></person-group><article-title>Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration</article-title><source>Cell</source><year>2006</year><volume>127</volume><fpage>59</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">17018277</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2006.09.015</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>St-Pierre</surname><given-names>J</given-names></name><name><surname>Drori</surname><given-names>S</given-names></name><name><surname>Uldry</surname><given-names>M</given-names></name><name><surname>Silvaggi</surname><given-names>JM</given-names></name><name><surname>Rhee</surname><given-names>J</given-names></name><name><surname>J&#x000e4;ger</surname><given-names>S</given-names></name><name><surname>Handschin</surname><given-names>C</given-names></name><name><surname>Zheng</surname><given-names>K</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Simon</surname><given-names>DK</given-names></name><name><surname>Bachoo</surname><given-names>R</given-names></name><name><surname>Spiegelman</surname><given-names>BM</given-names></name></person-group><article-title>Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators</article-title><source>Cell</source><year>2006</year><volume>127</volume><fpage>397</fpage><lpage>408</lpage><pub-id pub-id-type="pmid">17055439</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2006.09.024</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weydt</surname><given-names>P</given-names></name><name><surname>Pineda</surname><given-names>VV</given-names></name><name><surname>Torrence</surname><given-names>AE</given-names></name><name><surname>Libby</surname><given-names>RT</given-names></name><name><surname>Satterfield</surname><given-names>TF</given-names></name><name><surname>Lazarowski</surname><given-names>ER</given-names></name><name><surname>Gilbert</surname><given-names>ML</given-names></name><name><surname>Morton</surname><given-names>GJ</given-names></name><name><surname>Bammler</surname><given-names>TK</given-names></name><name><surname>Strand</surname><given-names>AD</given-names></name><name><surname>Cui</surname><given-names>L</given-names></name><name><surname>Beyer</surname><given-names>RP</given-names></name><name><surname>Easley</surname><given-names>CN</given-names></name><name><surname>Smith</surname><given-names>AC</given-names></name><name><surname>Krainc</surname><given-names>D</given-names></name><name><surname>Luquet</surname><given-names>S</given-names></name><name><surname>Sweet</surname><given-names>IR</given-names></name><name><surname>Schwartz</surname><given-names>MW</given-names></name><name><surname>La Spada</surname><given-names>AR</given-names></name></person-group><article-title>Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration</article-title><source>Cell Metab</source><year>2006</year><volume>4</volume><fpage>349</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">17055784</pub-id><pub-id pub-id-type="doi">10.1016/j.cmet.2006.10.004</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iglseder</surname><given-names>B</given-names></name><name><surname>Oberkofler</surname><given-names>H</given-names></name><name><surname>Felder</surname><given-names>TK</given-names></name><name><surname>Klein</surname><given-names>K</given-names></name><name><surname>Paulweber</surname><given-names>B</given-names></name><name><surname>Krempler</surname><given-names>F</given-names></name><name><surname>Tregouet</surname><given-names>DA</given-names></name><name><surname>Patsch</surname><given-names>W</given-names></name></person-group><article-title>Associations of PPARGC1A haplotypes with plaque score but not with intima-media thickness of carotid arteries in middle-aged subjects</article-title><source>Stroke</source><year>2006</year><volume>37</volume><fpage>2260</fpage><lpage>2265</lpage><pub-id pub-id-type="pmid">16902166</pub-id><pub-id pub-id-type="doi">10.1161/01.STR.0000238584.57864.d4</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Werner</surname><given-names>T</given-names></name></person-group><article-title>Computer-assisted analysis of transcription control regions. Matinspector and other programs</article-title><source>Methods Mol Biol</source><year>2000</year><volume>132</volume><fpage>337</fpage><lpage>349</lpage><pub-id pub-id-type="pmid">10547845</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weydt</surname><given-names>P</given-names></name><name><surname>Soyal</surname><given-names>S</given-names></name><name><surname>Gellera</surname><given-names>C</given-names></name><name><surname>DiDonato</surname><given-names>S</given-names></name><name><surname>Weidinger</surname><given-names>C</given-names></name><name><surname>Oberkofler</surname><given-names>H</given-names></name><name><surname>Landwehrmeyer</surname><given-names>B</given-names></name><name><surname>Patsch</surname><given-names>W</given-names></name></person-group><article-title>The gene coding for PGC-1alpha modifies age at onset in Huntington's Disease</article-title><source>Molecular Neurodegeneration</source><year>2009</year><volume>4</volume><fpage>3</fpage><pub-id pub-id-type="pmid">19133136</pub-id><pub-id pub-id-type="doi">10.1186/1750-1326-4-3</pub-id></citation></ref></ref-list></back></article> 